Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Jing Li, Zhenyu Li, Chunrui Li, Pengcheng He, Jun Luo, Rong Fu, Liye Zhong, Hang Quach, Jay Hocking, Peter Presgrave, Xiaoyi Tang, Wen Zhang, Jinchao Gao, Luyin Ding, Peiqi Li, Hui Zhou, Peng Liu
Institutions: Fudan University, Zhongshan Hospital, Tongji Hospital, Huazhong University of Science and Technology, First Affiliated Hospital of Xi'an Jiaotong University, Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University, Tianjin Medical University General Hospital, Tianjin Medical University, First Affiliated Hospital of Jinan University, St Vincent's Hospital Melbourne, Austin Hospital, Wollongong Hospital, Innovent Biologics (China)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417017897